Determinants of US Prescription Drug Utilization using County Level Data. (23rd April 2015)

• Record Type: Journal Article
• Authors: Nianogo, Thierry; Okunade, Albert; Fofana, Demba; Chen, Weiwei
• Is Part Of: Health economics. Volume 25:Number 5(2016)
• Page Start: 606
• Page End: 619
• Publication Date: 2015-04-23
• Subjects: prescription drugs -- Box–Cox transformation model -- US county data -- income elasticity; Medical economics -- Periodicals; Economics, Medical -- Periodicals; Health Care Costs -- Periodicals; Health Policy -- economics -- Periodicals; Health Services -- economics -- Periodicals; 362.1
• DOI: 10.1002/hec.3176
• Languages: English
• ISSNs: 1057-9230

Abstract

Summary: Prescription drugs are the third largest component of US healthcare expenditures. The 2006 Medicare Part D and the 2010 Affordable Care Act are catalysts for further growths in utilization becuase of insurance expansion effects. This research investigating the determinants of prescription drug utilization is timely, methodologically novel, and policy relevant. Differences in population health status, access to care, socioeconomics, demographics, and variations in per capita number of scripts filled at retail pharmacies across the USA justify fitting separate econometric models to county data of the states partitioned into low, medium, and high prescription drug users. Given the skewed distribution of per capita number of filled prescriptions (response variable), we fit the variance stabilizing Box–Cox power transformation regression models to 2011 county level data for investigating the correlates of prescription drug utilization separately for low, medium, and high utilization states. Maximum likelihood regression parameter estimates, including the optimal Box–Cox λ power transformations, differ across high ( λ = 0.214), medium ( λ = 0.942), and low ( λ = 0.302) prescription drug utilization models. The estimated income elasticities of −0.634, 0.031, and −0.532 in high, medium, and low utilization models suggest that the economic behavior of prescriptions is not invariant across different utilization levels. Copyright © 2015 John Wiley & Sons, Ltd.